Data Dashboard
HPV Vaccine Coverage Male/Female (adolescents age 13-17 years)
| Female 1-dose | Female Up-To-Date | Male 1-dose | Male Up-To-Date | |
| Kansas | 73.5% | 61.9% | 73.4% | 59.5% |
| United States | 77.8% | 64.6% | 74.4% | 60.6% |
HPV Vaccine Coverage Both Male and Female (adolescents age 13-17 years)
| Male and Female Up-To-Date | |
| Kansas | 60.7% |
| United States | 62.6% |
Key Vaccines Coverage
(combined 7-vaccine series for children 19-35 months | Tdap and menACWY for adolescents age 13-17 years | influenza for all persons over 6 months age)
| Combined 7- vaccine series* |
Tdap | MenACWY | Influenza | |
| Kansas | 65.3% | 89.2% | 85.9% | 47.6% |
| United States | 73.9% | 89.9% | 88.6% | 49.3% |
Human papillomavirus (HPV) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
Combined 7-vaccine Series Vaccination coverage among children 19-35 months by State, HHS Region, and the United States, National Immunization Survey-Child (NIS-Child), 2021
Tetanus-diphtheria toxoids (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
Meningococcal conjugate (MenACWY) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
Influenza vaccination coverage estimates for persons 6 months and older by state, HHS region, and the United States, National Immunization Survey-Flu (NIS-Flu) and Behavioral Risk Factor Surveillance System (BRFSS), 2020-21 influenza season
| Female | Male | Both Male & Female | ||||
| 1-dose | Up-To-Date | 1-dose | Up-To-Date | Up-To-Date | ||
| Kansas | 73.5% | 61.9% | 73.4% | 59.5% | 60.7% | |
| United States | 77.8% | 64.6% | 74.4% | 60.6% | 62.6% | |
| HP2030 Target | - | 80.0% | - | 80.0% | 80.0% | |
.png)
.png)
Human papillomavirus (HPV) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
Human Papillomavirus (HPV) vaccination coverage (1 dose or more) among adolescents aged 13-17 years in the United States, by area and parental report of provider recommendation status, National Immunization Survey-Teen (NIS-Teen), United States, 2018-2022
| MenACWY | |
| Kansas | 85.9% |
| United States | 88.6% |
| Target | 80.0% |
.png)
.png)
Meningococcal conjugate (MenACWY) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
| Tdap | |
| Kansas | 89.2% |
| United States | 89.9% |
| Target | 90.0% |
Tetanus-diphtheria toxoids (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination coverage among adolescents 13-17 years by State, HHS Region, and the United States, National Immunization Survey-Teen (NIS-Teen), 2022
| Children Age Group (Years) | |||
| 6 mo - 4 yrs | 5-12 yr | 13-17 yr | |
| Kansas | 63.5% | 58.8% | 47.5% |
| United States | 65.6% | 59.3% | 49.0% |
| Target | 70% | 70% | 70% |
| Age Group (Years) | |||
| 18+ | 18-64 | 65+ | |
| Kansas | 45.1% | 37.0% | 72.3% |
| United States | 46.9% | 40.0% | 69.7% |
| HP2020 Target | 70% | 70% | 70% |
| Kansas | ||
| Race | White | 49.5% |
| Black or African American | 42.4% | |
| Other/Multi-Race | 38.6% | |
| Ethnicity | Hispanic | 43.6% |
| 4+DTaP | 3+Polio | 1+MMR | Hib-FS | 3+HepB | 1+Var | 4+PCV | 2+HepA | Rotavirus | |
| Kansas | 98% | 91% | 87% | 78% | 89% | 88% | 77% | 76% | 79% |
| United States | 88% | 94% | 93% | 82% | 93% | 93% | 85% | 77% | 76% |
| Hib-FS | 3+HepB | 1+Var | |
| Kansas | 84% | 95% | 92% |
| United States | 84% | 94% | 94% |
| 4+PCV | 2+HepA | Rotavirus | |
| Kansas | 86% | 80% | 81% |
| United States | 86% | 78% | 77% |
ChildVaxView
| Age Group (Years) | ||
| 18-64yrs (At risk) |
65+yrs | |
| Kansas | 34% | 73% |
| United States | 31% | 70% |
| HP2020 Target | 60% | 90% |
* - At risk individuals: Individuals who have self-reported having one or more of the following: 1 )having current asthma; 2)ever being told by a health professional they have diabetes, myocardial infarction, angina or coronary heart disease; 3) being a current smoker; or 4) ever being told by a health professional they have chronic obstructive pulmonary disease, emphysema or chronic bronchitis, or cancer (excluding skin cancer).
Pneumococcal vaccination coverage among adults 18-64 years at increased risk and ≥65 years, Td and Tdap vaccination coverage among adults ≥18 years, and shingles vaccination among adults ≥60 years, by State, HHS Region, and the United States, BRFSS, 2022
The Kansas Department of Health and Environment conducts Immunization Coverage Assessments into the statewide vaccination records of various age groups across the state. The reports aim to provide an understanding of the vaccination coverages in the state and how they compare to the recommendations by the Advisory Committee for Immunization Practices (ACIP) and the American College Health Association (ACHA). A primary benefit to these reports is the ability to see vaccination coverage at a local level (e.g. by county), which is not possible through national resources. Click on the links below to view a highlight of the respective report's data, and a link report itself.
Kindergarten Immunization Coverage Survey
Dashboard:
Kindergarten Immunization Dashboard
Overview:
The Kindergarten Immunization Dashboard shows data from the Kindergarten Immunization Coverage Survey. The survey is a collection of vaccination records for children enrolled in a kindergarten class at Kansas public and private schools during the school year. Statewide vaccination coverage levels are calculated and various factors assessed. This study includes children between the ages of five and seven.
"The VaxView websites provide vaccination coverage data for all ages. Monitoring coverage for recommended vaccinations across the country helps CDC assess how well local areas, states, and the nation are protected from vaccine-preventable diseases." (CDC)